Alimera Sciences Inc.
| NASDAQ: ALIM | Healthcare / Drug Manufacturers / USA |
| 2.99 | -0.1100 | -3.55% | Vol 4.22K | 1Y Perf -38.98% |
| Oct 2nd, 2023 16:00 DELAYED |
| BID | 2.85 | ASK | 3.32 | ||
| Open | 3.16 | Previous Close | 3.10 | ||
| Pre-Market | - | After-Market | 2.85 | ||
| - - | -0.14 -4.68% |
| Target Price | 6.75 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 125.75 | Finscreener Ranking | ★★ 46.49 | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★+ 43.12 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ★★+ 47.18 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 34.14 | Earnings Rating | Strong Sell | |
| Market Cap | 26.32M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.22 | |
| Beta | 1.40 |
Today's Price Range 2.943.20 | 52W Range 1.306.25 | 5 Year PE Ratio Range -3.805.80 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.85% | ||
| 1 Month | -12.32% | ||
| 3 Months | 2.05% | ||
| 6 Months | 50.25% | ||
| 1 Year | -38.98% | ||
| 3 Years | -37.71% | ||
| 5 Years | -79.24% | ||
| 10 Years | -94.78% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 11.78 | |||
ROE last 12 Months | 70.46 | |||
ROA (5Y Avg) | -8.68 | |||
ROA last 12 Months | -39.09 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.90 | |||
Receivables Turnover | 2.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.10 | ||||
| 12.98 | ||||
| 0.49 | ||||
| 32.80 | ||||
| -2.00 | ||||
| -2.06 | ||||
| -0.53 | ||||
| -5.32 | ||||
| 77.68M | ||||
| Forward PE | 7.94 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.70 | ||||
| 0.90 | ||||
| - | ||||
| - | ||||
| -2.30 | ||||
| Leverage Ratio | -1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 85.50 | ||||
| -23.70 | ||||
| -18.80 | ||||
| -30.90 | ||||
| -35.73 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 40.10M | ||||
| 5.72 | ||||
| 4.50 | ||||
| 10.80 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | 0.06 | -0.44 | -833.33 |
| Q01 2023 | -0.58 | -0.71 | -22.41 |
| Q04 2022 | -0.28 | -0.54 | -92.86 |
| Q03 2022 | -0.37 | -0.75 | -102.70 |
| Q02 2022 | -0.61 | -0.45 | 26.23 |
| Q01 2022 | -0.67 | -0.85 | -26.87 |
| Q04 2021 | -0.38 | -0.59 | -55.26 |
| Q03 2021 | -0.52 | -0.60 | -15.38 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.41 | -612.50 | Negative |
| 12/2023 QR | -0.45 | -550.00 | Negative |
| 12/2023 FY | -0.01 | -106.25 | Negative |
| 12/2024 FY | 0.39 | -17.02 | Negative |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.41 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 4.22K |
| Shares Outstanding | 8.80K |
| Shares Float | 1.58M |
| Trades Count | 145 |
| Dollar Volume | 12.80K |
| Avg. Volume | 39.67K |
| Avg. Weekly Volume | 20.09K |
| Avg. Monthly Volume | 55.97K |
| Avg. Quarterly Volume | 42.95K |
Alimera Sciences Inc. (NASDAQ: ALIM) stock closed at 2.99 per share at the end of the most recent trading day (a -3.55% change compared to the prior day closing price) with a volume of 4.22K shares and market capitalization of 26.31M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 127 people. Alimera Sciences Inc. CEO is Richard S. Eiswirth.
The one-year performance of Alimera Sciences Inc. stock is -38.98%, while year-to-date (YTD) performance is 10.33%. ALIM stock has a five-year performance of -79.24%. Its 52-week range is between 1.3 and 6.25, which gives ALIM stock a 52-week price range ratio of 34.14%
Alimera Sciences Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 12.98, a price-to-sale (PS) ratio of 0.49, a price to cashflow ratio of 32.80, a PEG ratio of -, a ROA of -39.09%, a ROC of -% and a ROE of 70.46%. The company’s profit margin is -35.73%, its EBITDA margin is -18.80%, and its revenue ttm is $40.10 Million , which makes it $5.72 revenue per share.
Of the last four earnings reports from Alimera Sciences Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Alimera Sciences Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Alimera Sciences Inc. is Strong Buy (1), with a target price of $6.75, which is +125.75% compared to the current price. The earnings rating for Alimera Sciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alimera Sciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alimera Sciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 21.17, ATR14 : 0.25, CCI20 : -112.01, Chaikin Money Flow : -0.12, MACD : -0.07, Money Flow Index : 11.17, ROC : -11.80, RSI : 39.72, STOCH (14,3) : 13.48, STOCH RSI : 0.11, UO : 36.21, Williams %R : -86.52), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alimera Sciences Inc. in the last 12-months were:
Alimera Sciences Inc.
Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN(R) is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. A $2B global market, DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema leading to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology.
CEO: Richard S. Eiswirth
Telephone: +1 678 990-5740
Address: 6120 Windward Parkway, Alpharetta 30005, GA, US
Number of employees: 127
TipRanks News for ALIM
Wed, 27 Sep 2023 12:30 GMT Six new option listings on September 27th
- TipRanks. All rights reserved.
